
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:title>Biologic therapies for treatment of asthma associated with type 2 inflammation : effectiveness, value, and value-based price benchmarks : final evidence report</dc:title>
  <dc:subject>Antibodies, Monoclonal -- therapeutic use</dc:subject>
  <dc:subject>Asthma -- drug therapy</dc:subject>
  <dc:subject>Inflammation -- drug therapy</dc:subject>
  <dc:publisher>[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2018</dc:publisher>
  <dc:contributor>Institute for Clinical and Economic Review, issuing body.</dc:contributor>
  <dc:contributor>Midwest Comparative Effectiveness Public Advisory Council, issuing body.</dc:contributor>
  <dc:type>Technical Report</dc:type>
  <dc:format>Text</dc:format>
  <dc:format>Illustrations</dc:format>
  <dc:format>1 online resource (1 PDF file (1 (various pagings))</dc:format>
  <dc:identifier>nlm:nlmuid-101745064-pdf</dc:identifier>
  <dc:identifier>101745064</dc:identifier>
  <dc:identifier>http://resource.nlm.nih.gov/101745064</dc:identifier>
  <dc:language>English</dc:language>
  <dc:coverage>United States</dc:coverage>
  <dc:rights>Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. http://creativecommons.org/licenses/by/4.0</dc:rights>
</oai_dc:dc>